 InPharm |
Pfizer Lung Cancer Drug to Get Priority Review
Xconomy New York-based Pfizer (NYSE: PFE) announced that it has simultaneously applied for approval of its lung cancer drug, crizotinib, in the US and Japan, and that the FDA granted it priority review. Crizotinib is the first in a new class of drugs called … Pfizer accelerates Crizotinib regulatory procedures FDA Grants Pfizer Priority Review For Lung Cancer Drug Pfizer lung cancer drug – Is FDA becoming more Open to Experimental Therapies? |
View full post on lung cancer – Google News
